small molecule

AKLIEF

TRIFAROTENE

Loss of exclusivityMay 2033latest FDA-listed patent expiry
CompanyGALDERMA LABORATORIES LP

Drug detail

Brand nameAKLIEF
Active ingredientTRIFAROTENE
Strength0.005%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalOctober 2019
Marketing statusRX

Listed patents

PatentExpiresType
9084778May 2033product
9498465May 2033product
7807708July 2031substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AKLIEF patent cliff — loss of exclusivity May 2033 | CliffBio